Editorial: Advancement of chemotherapy in breast cancer: predictive markers, resistance mechanism and therapeutic strategies
-
By
-
Richard Beatson
-
Jinhai Deng
-
Teng Pan
-
Zhendong Shi
-
Ming Zhao
-
July 3, 2026
-
Clinical Scorecard: Progress in Breast Cancer Chemotherapy: Predictive Biomarkers, Mechanisms of Resistance, and Treatment Approaches
At a Glance
| Category | Detail |
|---|
| Condition | Breast Cancer |
| Key Mechanisms | Predictive biomarkers, resistance mechanisms, therapeutic strategies |
| Target Population | Breast cancer patients undergoing chemotherapy |
| Care Setting | Oncology clinical trials and research |
Key Highlights
- Pentoxifylline significantly reduces chemotherapy-induced neuropathy and mucositis.
- Trimetazidine effectively mitigates paclitaxel-induced peripheral neuropathy.
- Systemic Immune-Inflammation Index (SII) shows potential as a prognostic tool for breast cancer.
- High biopsy-sTILs and Ki67 predict pathological complete response in triple-negative breast cancer.
- Therapeutic drug monitoring of docetaxel optimizes dosing and minimizes toxicity.
Guideline-Based Recommendations
Diagnosis
- Utilize MRI for evaluating treatment response post-neoadjuvant therapy.
Management
- Consider co-administration of pentoxifylline and trimetazidine to reduce neuropathy.
Monitoring & Follow-up
- Implement therapeutic drug monitoring for docetaxel to manage adverse reactions.
Risks
- Monitor for increased hematologic toxicity with dexrazoxane co-administration.
Patient & Prescribing Data
Breast cancer patients undergoing chemotherapy, including those with triple-negative subtype.
Personalized medicine approaches are necessary to optimize treatment based on predictive biomarkers.
Clinical Best Practices
- Incorporate predictive biomarkers in treatment planning.
- Utilize nomograms for predicting treatment outcomes.
- Monitor patients closely for adverse effects during chemotherapy.
Related Resources & Content
